Icecure Medical (ICCM)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $3.39M
Last updated: Nov 17, 2026 at 11:03 AM ET
Icecure Medical (ICCM) Earnings: Report Dates and Results
Icecure Medical (ICCM) is confirmed to report earnings on Nov 18, 2026, before the open. In the quarter ended Jun 30, 2026, Icecure Medical reported EPS of -$3.11, below the -$1.37 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ICCM has a confirmed report date of Nov 18, 2026, before the open.
ICCM Earnings Call
The latest ICCM earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 18 quarters below that had an estimate, ICCM beat 7, missed 8 and matched 3. Revenue for the quarter ended Jun 30, 2026 was $907000, up 72.8% from $525000 a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | -$3.11 | -$1.37 | -$1.80 - -$0.95 | -127.01% | Miss | N/A | 2 | 0 up, 1 down | Aug 12, 2026 | $907000 |
| Mar 31, 2026 | -$0.06 | -$0.05 | -$0.05 - -$0.03 | -16.20% | Miss | N/A | 2 | 1 up, 0 down | May 12, 2026 | $911000 |
| Dec 31, 2025 | -$1.80 | -$1.20 | -$1.20 - -$1.20 | -50.00% | Miss | N/A | 1 | 1 up, 0 down | Mar 17, 2026 | $1.28M |
| Sep 30, 2025 | -$1.80 | -$1.65 | -$1.80 - -$1.50 | -9.09% | Miss | N/A | 2 | 2 up, 0 down | Nov 19, 2025 | $850000 |
| Jun 30, 2025 | -$1.80 | -$1.95 | -$2.10 - -$1.80 | +7.69% | Beat | N/A | 2 | 0 up, 1 down | Aug 13, 2025 | $525000 |
| Mar 31, 2025 | -$1.80 | -$2.40 | -$2.40 - -$2.40 | +25.00% | Beat | N/A | 2 | 0 up, 1 down | May 28, 2025 | $725000 |
| Dec 31, 2024 | -$0.08 | -$0.08 | N/A | 0.00% | In line | N/A | 1 | 1 up, 0 down | Mar 27, 2025 | $875000 |
| Sep 30, 2024 | -$2.40 | -$2.25 | -$2.40 - -$2.10 | -6.67% | Miss | N/A | 2 | 0 up, 1 down | Nov 26, 2024 | $662000 |
| Jun 30, 2024 | -$1.80 | -$2.10 | -$2.10 - -$2.10 | +14.29% | Beat | N/A | 2 | 0 up, 0 down | Aug 20, 2024 | $1.01M |
| Mar 31, 2024 | -$2.40 | -$2.40 | -$2.40 - -$2.40 | 0.00% | In line | N/A | 2 | 0 up, 0 down | Apr 3, 2024 | $743000 |
| Dec 31, 2023 | -$0.06 | -$0.08 | -$0.08 - -$0.06 | +21.77% | Beat | N/A | 3 | 0 up, 0 down | Feb 20, 2024 | $1.25M |
| Sep 30, 2023 | -$2.61 | -$2.70 | -$2.70 - -$2.70 | +3.33% | Beat | N/A | 3 | 0 up, 0 down | Nov 15, 2023 | $327000 |
| Jun 30, 2023 | -$2.64 | -$2.60 | -$2.70 - -$2.40 | -1.54% | Miss | N/A | 3 | 0 up, 0 down | Aug 14, 2023 | $937000 |
| Mar 31, 2023 | -$2.40 | -$2.80 | -$3.00 - -$2.70 | +14.29% | Beat | -2100.0% | 3 | 0 up, 0 down | May 22, 2023 | $710000 |
| Dec 31, 2022 | -$0.11 | -$0.10 | -$0.11 - -$0.09 | -10.00% | Miss | N/A | 3 | 0 up, 0 down | Mar 29, 2023 | $939000 |
| Sep 30, 2022 | -$3.30 | -$3.45 | -$3.60 - -$3.30 | +4.35% | Beat | N/A | 2 | 0 up, 0 down | Dec 5, 2022 | $634000 |
| Jun 30, 2022 | -$3.72 | -$3.60 | N/A | -3.33% | Miss | N/A | N/A | N/A | Aug 15, 2022 | $765000 |
| Mar 31, 2022 | $0.12 | $0.12 | N/A | 0.00% | In line | N/A | N/A | N/A | Apr 1, 2022 | $747000 |
| Jun 30, 2021 | -$0.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 23, 2021 | $637000 |
| Mar 31, 2021 | -$0.08 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 12, 2021 | $1.44M |
| Dec 31, 2020 | -$0.08 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2021 | $1.38M |
| Sep 30, 2020 | -$0.07 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2020 | $635000 |
| Jun 30, 2020 | -$0.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2020 | $927500 |
| Mar 31, 2020 | -$0.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 30, 2020 | $927500 |
| Dec 31, 2019 | -$0.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2020 | $539194 |
| Sep 30, 2019 | -$0.08 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2019 | $535642 |
| Jun 30, 2019 | -$0.08 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2019 | $282439 |
| Mar 31, 2019 | -$0.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 30, 2019 | $277479 |
| Dec 31, 2018 | -$0.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2019 | $332121 |
| Sep 30, 2018 | -$0.08 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2018 | $285093 |
| Mar 31, 2018 | -$0.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 30, 2018 | $251747 |
| Dec 31, 2017 | -$0.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2018 | $58340 |
| Sep 30, 2017 | -$0.11 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2017 | $171414 |
| Jun 30, 2017 | -$0.12 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2017 | $227474 |
| Mar 31, 2017 | -$0.11 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 30, 2017 | $219083 |
| Dec 31, 2016 | -$3.81 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2017 | $90421 |
| Sep 30, 2016 | -$0.12 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2016 | $203086 |
| Jun 30, 2016 | -$0.13 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2016 | $162550 |
| Mar 31, 2016 | -$0.19 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2016 | $178215 |
| Dec 31, 2015 | -$0.34 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2016 | $245435 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$7.20, after -$6.68 the year before. It was -$1.09 for the year ended Dec 31, 2015, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$7.20 | N/A |
| Dec 31, 2024 | -$6.68 | N/A |
| Dec 31, 2023 | -$7.71 | N/A |
| Dec 31, 2022 | -$7.18 | N/A |
| Dec 31, 2020 | -$0.29 | N/A |
| Dec 31, 2019 | -$0.30 | N/A |
| Dec 31, 2018 | -$0.26 | N/A |
| Dec 31, 2017 | -$0.43 | N/A |
| Dec 31, 2016 | -$4.25 | N/A |
| Dec 31, 2015 | -$1.09 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 3,600 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 3,637 | 7 | |
| 2026Q1 | Mar 31, 2026 | 3,409 | 7 | |
| 2025Q4 | Dec 31, 2025 | 3,397 | 6 | |
| 2025Q3 | Sep 30, 2025 | 2,509 | 5 | |
| 2025Q2 | Jun 30, 2025 | 3,411 | 7 | |
| 2025Q1 | Mar 31, 2025 | 2,911 | 7 | |
| 2024Q2 | Jun 30, 2024 | 2,993 | 7 |
2026Q2 Earnings Call
Opening remarks
Eyal Shamir CEO Thank you, operator, and thank you, everyone, for joining us today. The first half of 2026 marks an important inflection point for IceCure. Over the past several years, we have focused on building the clinical, regulatory and scientific foundation for ProSense. We invested in generating clinical evidence, achieving important regulatory milestones and educating physicians around the world. Today, we are beginning to see those investments translate into measurable commercial momentum while continuing to generate the evidence that supports future growth. We believe what makes this stage of our evolution particularly important is that our clinical and commercial strategies are no longer progressing on separate tracks. They are increasingly reinforcing one another. Growing physician adoption generates additional real-world clinical experience, yet expands both the breadth of evidence to answer physician confidence, support future reimbursement initiatives and encourage broader adoption. As more physicians adopt ProSense, they generate additional real-world evidence creating a self-reinforcing cycle that we believe will continue to strengthen over time. This is exactly the transition we have been working towards. During the first half of the year, revenue increased approximately 45% year over year to $1.8 million, driven by growth of both ProSense systems and disposable products. More importantly, this growth reflects increasing physician adoption and utilization of our technology across our commercial installed base. One of the most meaningful metrics of commercial progress is not simply the number of systems placed, but how frequently those systems are being used. Increasing disposable probe utilization suggests that physicians are incorporating ProSense into routine clinical practice and treating more patients over time. This recurring utilization gives us confidence that commercial adoption is becoming broader, deeper and increasingly sustainable. Following FDA clearance for early-stage, low-risk breast cancer, we continue expanding our U.S. commercial footprint, achieving approximately 70% growth in our active U.S. commercial installed base. At the same time, we are strengthening our commercial organization through additional sales hires in key U.S. regions while continuing to expand our presence across select international markets. Another important example of how our clinical and commercial strategies are coming together is our FDA-approved CHOICE post-market study. I would like to emphasize an important point regarding the CHOICE study. Unlike traditional pre-market clinical studies, the CHOICE trial is a post-market study and is not separate from our commercialization strategy. Rather it is an extension of it. Participating clinical sites purchase disposable probes as part of routine patient care while simultaneously contributing valuable real-world clinical evidence. Some participating physicians have already transitioned from clinical investigators into active commercial users of ProSense, while additional leading institutions are joining the study and becoming new users of our technology.
Frequently Asked Questions About ICCM
When is Icecure Medical's next earnings date?
Icecure Medical's next earnings report is confirmed for Nov 18, 2026, before the open.
Did ICCM beat earnings estimates last quarter?
No. Icecure Medical reported EPS of -$3.11 for the quarter ended Jun 30, 2026, below the -$1.37 estimate by 127.01%.
What EPS do analysts expect from ICCM next quarter?
The consensus EPS estimate for Icecure Medical for the quarter ended Sep 30, 2026 is -$0.83 from 1 analyst, with estimates from -$0.83 to -$0.83.
How often does ICCM beat earnings estimates?
Icecure Medical beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -22.03%.
Does ICCM report before or after the market opens?
Icecure Medical is confirmed to report on Nov 18, 2026, before the market opens.
ICCM pages: Overview, Earnings, Forecast, Financials, Competitors